• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 23, 2015

View Archived Issues

Xoma shares plummet on gevokizumab setback

Xoma Corp. highlighted its early stage pipeline Wednesday as its lead product candidate gevokizumab added another clinical failure to the record, which already included midstage busts in erosive osteoarthritis and type 2 diabetes. Read More

Eiger lines up series B while readying for new orphan ventures

Eiger Biopharmaceuticals Inc., a start-up seeking to develop a cure for chronic hepatitis delta virus (HDV), is on the verge of closing a series B financing that will help it advance its lead candidate, lonafarnib, while also broadening its portfolio to include multiple phase II, orphan-designated programs. Read More

Junk DNA into treasure: Rana bolstering RNA R&D with $55M series B

Rana Therapeutics Inc., a young firm quietly building up RNA platform technology, padded its coffers with a $55 million series B round to advance its lead programs toward the clinic and expand its in-house capabilities. Read More

Mixed progress but no breakthroughs solving Alzheimer's puzzle

Patients, investors and analysts seeking irrefutable evidence of progress in curing or mitigating the effects of Alzheimer's disease (AD) were likely disappointed when a flurry of trial results and data analyses presented Wednesday at the Alzheimer's Association International Conference (AAIC) in Washington suggested steps forward, but still no breakthroughs on the horizon. Read More

Target hunting uses superhero DNA

Editor's note: With this week's EU approval of Repatha and the upcoming FDA decision on Praluent, BioWorld is looking back on the discovery of the PCSK9 gene that both drugs target. Read More

UK biopharmas boost coffers: Kalvista brings in $33M; Motif lands $34M

LONDON – Kalvista Pharmaceutical has raised $33 million in a series B round, providing the means to diversify its plasma kallikrein inhibitors into the treatment of hereditary angioedema (HAE) while advancing its diabetic macular edema (DME) program to clinical proof of concept. Read More

Regulatory front

The Senate Finance Committee voted 23-3 Tuesday to advance a bill that would extend the R&D tax credit for another two years. The credit, used by many drug- and device-makers, expired Jan. 1, along with several other tax incentives. Read More

Stock movers

Read More

Financings

Fibrocell Science Inc., of Exton, Pa., said it has begun an underwritten public offering and intends to use the net proceeds of the proposed offering for the continued clinical and preclinical development of its product candidates and for other general corporate purposes. Read More

Other news to note

Cardiome Pharma Corp., of Vancouver, British Columbia, said it submitted a supplemental new drug submission to Health Canada's Therapeutic Products Directorate for Aggrastat (tirofiban hydrochloride). Read More

In the clinic

Astrazeneca plc, of London, said the phase III SUMIT study of selumetinib in combination with dacarbazine to treat patients with metastatic uveal melanoma missed its primary endpoint of progression-free survival. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe